Formulation and evaluation of microspheres containing ropinirole hydrochloride using biodegradable polymers

Jyotsana R. Madan, Vinod Kadam, Sudarshan Bandavane, Kamal Dua

Abstract


The present work relates with developing long acting sustain release microspheres of ropinirole hydrochloride (RPN) for
treatment of Parkinson’s disease, that will sustain drug release up to 1 month. Biodegradable microspheres of RPN were
prepared by using two different polymers (poly lactic co glycolic acid [PLGA] 50:50 and PLGA 75:25) employing double
emulsion (W/O/W) solvent evaporation method. Preliminary optimization of process parameter was done for concentration
of polyvinyl alcohol (PVA) solution, stirring speed, temperature of PVA solution, ratio of the drug to polymer (D/P) and
ratio of internal phase to external phase volume (IP/EP). All formulations were evaluated for particle size, percentage yield,
entrapment efficiency (EE), shape etc. Formulation E3 and E4 shows maximum EE. % in vitro drug release per day of E3 and
E4 batch was studied. The RPN was incorporated successfully in microspheres prepared with 0.5% w/v PVA at 8000 RPM
stirring speed, 20°C processing temperature, 1:4 drug polymer ratio and 1:30 IP/EP ratio, which provides sustained release
up to 4 weeks with better efficacy and patient compliance and can be employed as an alternative to existing oral medications.
Key words: Entrapment efficiency, poly lactic co glycolic acid 50:50, polyvinyl alcohol, solvent evaporation, sustained release

Full Text:

PDF

References


Chaudhuri RK, Martinez-Martin P, Rolfe KA, Cooper J, Rockett CB,

Giorgi L. Improvements in nocturnal symptoms with ropinirole

prolonged release in patients with advanced Parkinson’s disease. Eur

J Neurol 2012;19:105-13.

Eden RJ, Costall B, Domeney AM, Gerrard PA, Harvey CA, Kelly ME, et al.

Preclinical pharmacology of ropinirole (SK and F 101468‑A) a novel

dopamine D2 agonist. Pharmacol Biochem Behav 1991;38:147‑54.

Hatefi A, Amsden B. Biodegradable injectable in situ forming drug

delivery systems. J Control Release 2002;80:9‑28.

Berkland C, Kim K, Pack DW. Fabrication of PLG microspheres with

precisely controlled and monodisperse size distributions. J Control

Release 2001;73:59‑74.

Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH. Controlled

release of drugs from injectable in situ formed biodegradable PLGA

microspheres: Effect of various formulation variables. Eur J Pharm

Biopharm 2000;50:257‑62.

Sun Y, Wang J, Zhang X, Zhang Z, Zheng Y, Chen D, et al. Synchronic release

of two hormonal contraceptives for about one month from the PLGA

microspheres: In vitro and in vivo studies. J Control Release 2008;129:192‑9.

Jeffery H, Davis SS, O’Hagan DT. The preparation and characterization of

poly (lactide‑co‑glycolide) microparticles. II. The entrapment of a model

protein using a (water‑in‑oil)‑in‑water emulsion solvent evaporation

technique. Pharm Res 1993;10:362‑8.

Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable

poly (lactic‑co‑glycolic acid) microparticles for injectable delivery of

vaccine antigens. Adv Drug Deliv Rev 2005;57:391‑410.

Gu H, Song C, Long D, Mei L, Sun H. Controlled release of recombinant

human nerve growth factor (rhNGF) from poly[(lactic acid)‑co‑(glycolic

acid)] microspheres for the treatment of neurodegenerative disorders.

Polym Int 2007;56:1272‑80.

Conway BR, Oya AH. Double emulsion microencapsulation of proteins

as model antigens using polylactide polymers: effect of emulsifiers on

microsphere characteristics and release kinetics. Eur J Pharm Biopharm

;42:42‑8.

Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T. A new

technique to efficiently entrap leuprolide acetate into microcapsules of

polylactic acid or copoly (lactic/glycolic) acid. Chem Pharm Bull (Tokyo)

;36:1095‑103.

Aubert‑Pouëssel A, Venier‑Julienne MC, Clavreul A, Sergent M,

Jollivet C, Montero‑Menei CN, et al. In vitro study of GDNF release from

biodegradable PLGA microspheres. J Control Release 2004;95:463‑75.

Prior S, Gamazo C, Irache JM, Merkle HP, Gander B. Gentamicin

encapsulation in PLA/PLGA microspheres in view of treating Brucella

infections. Int J Pharm 2000;196:115‑25.

Zolnik BS, Burgess DJ. Evaluation of in vivo‑in vitro release of

dexamethasone from PLGA microspheres. J Control Release

;127:137‑45.

Arshady R. Preparation of biodegradable microspheres and

microcapsules: Polylactides and related polyesters. J Control Release

;17:1‑22.

Parikh RH, Parikh JR, Dubey RR, Soni HN, Kapadia KN. Poly (D,

L‑lactide‑co‑glycolide) microspheres containing 5‑fluorouracil:

Optimization of process parameters. AAPS Pharm Sci Tech 2003;4:E13.

Lee SC, Oh JT, Jang MH, Chung SI. Quantitative analysis of polyvinyl

alcohol on the surface of poly (D, L‑lactide‑co‑glycolide) microparticles

prepared by solvent evaporation method: Effect of particle size and

PVA concentration. J Control Release 1999;59:123‑32.

Yang YY, Chung TS, Bai XL, Chan WK. Effect of preparation conditions

on morphology and release profiles of biodegradable polymeric

microspheres containing protein fabricated by double‑emulsion

method. Chem Eng Sci 2000;55:2223‑36.

Lu L, Peter SJ, Lyman MD, Lai HL, Leite SM, Tamada JA, et al. In vitro and

in vivo degradation of porous poly (DL‑lactic‑co‑glycolic acid) foams.

Biomaterials 2000;21:1837‑45.

Park TG. Degradation of poly (lactic‑co‑glycolic acid) microspheres:

Effect of copolymer composition. Biomaterials 1995;16:1123‑30.

Makadia HK, Siegel SJ. Poly lactic‑co‑glycolic acid (PLGA) as

biodegradable controlled drug delivery carrier. Polymers (Basel)

;3:1377‑97.




DOI: http://dx.doi.org/10.22377/ajp.v7i4.342

Refbacks

  • There are currently no refbacks.